Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term CagriSema versus placebo for obesity
2024-512144-39-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 6
01
Overview
Phase 3, randomised trial of cagrilintide and semaglutide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change in body weight. Planned start Jan 2025; status: authorised.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on 2024-512144-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512144-39-00.